

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

) Art Unit: 1627

) LADNER, et al.

) Examiner: CELSA, Bennett

) Serial No.: 09/896,095

) Confirmation No. 8370

) Filed: June 29, 2001

) Washington, D.C.

) For: DIPECTED EVOLUTION  
) OF NOVEL BINDING PROTEINS)

) May 8, 2002

) Docket No.: LADNER=7L

PRELIMINARY AMENDMENT

Commissioner of Patents  
Washington, D.C. 20231

S i r :

IN THE SPECIFICATION

Please replace the paragraph beginning at page 34, lines 24-27, with the following rewritten paragraph:

--BPTI

Bovine pancreatic trypsin inhibitor, identical to aprotinin (Merck Index, entry 784, p.119 (SEQ ID NO:44))--

Please replace the paragraph on page 38, lines 10-18, with the following rewritten paragraph:

--A candidate IPBD should meet the following criteria:

- 1) a domain exists that will remain stable under the conditions of its intended use (the domain may comprise the entire protein that will be inserted, e.g. BPTI (SEQ ID NO:44),  $\alpha$ -conotoxin GI, or CMTI-III),
- 2) knowledge of the amino acid sequence is obtainable, and
- 3) a molecule is obtainable having specific and high affinity for the IPBD, AfM (IEBD).--

Please replace the paragraph on pages 50-51, lines 13-34 and 1-8, with the following rewritten paragraph:

--Polypeptides of this size, however, have disadvantages as binding molecules. According to Olivera et al. (OLIV90a):